Loading...
XNAS
OSUR
Market cap292mUSD
Jul 09, Last price  
4.29USD
1D
0.82%
1Q
44.76%
Jan 2017
-51.20%
Name

OraSure Technologies Inc

Chart & Performance

D1W1MN
XNAS:OSUR chart
P/E
P/S
2.56
EPS
Div Yield, %
Shrs. gr., 5y
1.71%
Rev. gr., 5y
-7.70%
Revenues
115m
-38.10%
68,154,92082,685,87671,104,46777,026,22675,014,83681,881,29887,820,00098,940,000106,464,000119,719,000122,798,000167,064,000181,743,000154,605,000171,721,000233,674,000387,479,000405,472,000185,827,000115,021,000
Net income
-69m
L+252.47%
5,267,5492,472,439-31,275,302-7,813,133-3,496,945-8,840,619-15,115,000-11,190,000-4,614,0008,167,00019,720,00030,948,00020,396,00016,655,999-14,922,000-22,998,000-17,133,00053,655,000-19,500,000-68,731,000
CFO
-49k
L
16,885,80411,583,879-2,460,342-292,7653,887,167-2,993,9845,372,0008,286,0007,526,00015,773,00022,767,00028,156,00039,090,0009,804,0005,807,000-35,382,000-47,202,000141,583,00027,374,000-49,023
Dividend
Jan 08, 19981.6 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
IPO date
Nov 17, 1986
Employees
840
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT